|
Post by Omega on Sept 27, 2018 17:26:48 GMT -5
50-75% per share below 2014 post approval price. Not everyone would be happy with that. It would sure be a nice start and a welcome development, most everyone would be pretty happy with it, after averaging down considerably since that post-approval time. I have 10X the shares I had back in 2014, I'd have no problem with getting to 50-75% of that price, and it would only continue to go up from there.
|
|
|
Post by cjc04 on Sept 27, 2018 17:33:19 GMT -5
and when we’re finally valued where we should be, $2b to $4b, I’ll be just fine with 200 mil shares. 50-75% per share below 2014 post approval price. Not everyone would be happy with that. you're choosing to miss the point.... you’re complaining about dilution, but if that’s what it took to survive, and we make it back to a $2b, $4b, or $10b cap, then it was worth it for everyone. There is NO logical argument against that.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 27, 2018 17:40:15 GMT -5
50-75% per share below 2014 post approval price. Not everyone would be happy with that. you're choosing to miss the point.... you’re complaining about dilution, but if that’s what it took to survive, and we make it back to a $2b, $4b, or $10b cap, then it was worth it for everyone. There is NO logical argument against that. Damn it. Said I wouldnt post until xmas. BUT GOTTA SAY. Traderdennis = debbie downer.
|
|
|
Post by traderdennis on Sept 27, 2018 19:03:04 GMT -5
you're choosing to miss the point.... you’re complaining about dilution, but if that’s what it took to survive, and we make it back to a $2b, $4b, or $10b cap, then it was worth it for everyone. There is NO logical argument against that. Damn it. Said I wouldnt post until xmas. BUT GOTTA SAY. Traderdennis = debbie downer. rofl
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 27, 2018 19:57:38 GMT -5
Damn it. Said I wouldnt post until xmas. BUT GOTTA SAY. Traderdennis = debbie downer. rofl Want to also add. Still buying weekly. When we hit a market cap of $10b I am going to laugh like Jabba the Hut when he bargins for Solo with Princess Leia. youtu.be/OPcod8IS214
|
|
|
Post by barnstormer on Sept 27, 2018 23:32:23 GMT -5
|
|
|
Post by prcgorman2 on Sept 28, 2018 6:38:41 GMT -5
It is a lot of the real story. It misses out that the more than $1B deal MannKind struck with Sanofi was with Chris Viehbacher then CEO of Sanofi. Viehbacher was replaced by the Sanofi board a few months after the deal was inked with Oliver Brandicoot who had been the executive in charge of the wasteful disaster that was the Exubera launch at Pfizer. Whether that move from Viehbacher to Brandicoot was engineered by money paid to insure MannKind was orphaned or just bad luck, it wouldn't be hard to argue that Brandicoot had a bad taste in his mouth regarding inhalable insulin from his monumental failure at Pfizer. The story also misses that Sanofi was also sued to the tune of $700M+ by former Genzyme shareholders and Chris Viehbacher who had been the Chairman of Genzyme before being given the CEO job at Sanofi. The reason for the giant lawsuit? Sanofi reneged on a drug development agreement they had made with Genzyme. Sound familiar?
The reason I point out these details is to highlight that there were personal choices made at the very top of Sanofi's leadership which directly and negatively impacted the marketing of Afrezza and the value of MannKind stock. The hurdles that are mentioned with regard to Afrezza marketing such as black box warning on the label, prior auth, et cetera are indeed part of the picture but ittle MannKind with it's meager resources has been able to essentially equal Sanofi sales results. To me this argues that Sanofi sandbagged MannKind the instant Brandicoot took over as CEO in February of 2015. Brandicoot is still CEO of Sanofi which has enjoyed an approximately 20% decline in it's stock price under Brandicoot's "leadership".
I was bitter at first, but I'm over it now.
|
|
|
Post by barnstormer on Sept 28, 2018 8:19:34 GMT -5
Agreed, if Viehbacher was still at SNY our story would have been different. Too bad he isn't on the BOD of MNKD. Brandicourt lacks vision and we all know slow played the Afrezza rollout. I think his days are short at SNY. Just my opinion. The good news is MNKD has engineered a comeback. Now Mike needs to bring in another partner with cash and SNY will fade from the rear view mirror.
|
|
|
Post by prcgorman2 on Sept 28, 2018 13:15:52 GMT -5
New international partner would be my preference. I like MannKind keeping marketing control in USA. Burn me once, shame on you. Burn me twice, shame on me.
|
|
|
Post by rockstarrick on Sept 28, 2018 13:44:14 GMT -5
It is a lot of the real story. It misses out that the more than $1B deal MannKind struck with Sanofi was with Chris Viehbacher then CEO of Sanofi. Viehbacher was replaced by the Sanofi board a few months after the deal was inked with Oliver Brandicoot who had been the executive in charge of the wasteful disaster that was the Exubera launch at Pfizer. Whether that move from Viehbacher to Brandicoot was engineered by money paid to insure MannKind was orphaned or just bad luck, it wouldn't be hard to argue that Brandicoot had a bad taste in his mouth regarding inhalable insulin from his monumental failure at Pfizer. The story also misses that Sanofi was also sued to the tune of $700M+ by former Genzyme shareholders and Chris Viehbacher who had been the Chairman of Genzyme before being given the CEO job at Sanofi. The reason for the giant lawsuit? Sanofi reneged on a drug development agreement they had made with Genzyme. Sound familiar? The reason I point out these details is to highlight that there were personal choices made at the very top of Sanofi's leadership which directly and negatively impacted the marketing of Afrezza and the value of MannKind stock. The hurdles that are mentioned with regard to Afrezza marketing such as black box warning on the label, prior auth, et cetera are indeed part of the picture but ittle MannKind with it's meager resources has been able to essentially equal Sanofi sales results. To me this argues that Sanofi sandbagged MannKind the instant Brandicoot took over as CEO in February of 2015. Brandicoot is still CEO of Sanofi which has enjoyed an approximately 20% decline in it's stock price under Brandicoot's "leadership". I was bitter at first, but I'm over it now. I’m over it too,,,,, unless I ran into Brandicourt in a bar. 🥊😜
|
|
|
Post by goyocafe on Sept 28, 2018 14:56:13 GMT -5
It is a lot of the real story. It misses out that the more than $1B deal MannKind struck with Sanofi was with Chris Viehbacher then CEO of Sanofi. Viehbacher was replaced by the Sanofi board a few months after the deal was inked with Oliver Brandicoot who had been the executive in charge of the wasteful disaster that was the Exubera launch at Pfizer. Whether that move from Viehbacher to Brandicoot was engineered by money paid to insure MannKind was orphaned or just bad luck, it wouldn't be hard to argue that Brandicoot had a bad taste in his mouth regarding inhalable insulin from his monumental failure at Pfizer. The story also misses that Sanofi was also sued to the tune of $700M+ by former Genzyme shareholders and Chris Viehbacher who had been the Chairman of Genzyme before being given the CEO job at Sanofi. The reason for the giant lawsuit? Sanofi reneged on a drug development agreement they had made with Genzyme. Sound familiar? The reason I point out these details is to highlight that there were personal choices made at the very top of Sanofi's leadership which directly and negatively impacted the marketing of Afrezza and the value of MannKind stock. The hurdles that are mentioned with regard to Afrezza marketing such as black box warning on the label, prior auth, et cetera are indeed part of the picture but ittle MannKind with it's meager resources has been able to essentially equal Sanofi sales results. To me this argues that Sanofi sandbagged MannKind the instant Brandicoot took over as CEO in February of 2015. Brandicoot is still CEO of Sanofi which has enjoyed an approximately 20% decline in it's stock price under Brandicoot's "leadership". I was bitter at first, but I'm over it now. I’m over it too,,,,, unless I ran into Brandicourt in a bar. 🥊😜 Or they come back to the table with 20 billion in their small, outreached hands.
|
|